Stay updated on IGF-1/IGFBP3 for ROP Prevention Clinical Trial

Sign up to get notified when there's something new on the IGF-1/IGFBP3 for ROP Prevention Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the IGF-1/IGFBP3 for ROP Prevention Clinical Trial page

  1. Check
    6 days ago
    No Change Detected
  2. Check
    13 days ago
    Change Detected
    Summary
    The NIH banner about terminology updates and related FAQs is no longer displayed; the page still shows a 403 Forbidden message.
    Difference
    1%
    Check dated 2026-11-09T13:22:04.000Z thumbnail image
  3. Check
    20 days ago
    Change Detected
    Summary
    The footer revision label changes from v3.7.2 to v3.8.0, while the page continues to show a 403 Forbidden error.
    Difference
    0.2%
    Check dated 2026-11-02T13:17:30.000Z thumbnail image
  4. Check
    27 days ago
    Change Detected
    Summary
    A sitewide NIH notice announces updates about the transition from “Artificial Intelligence” to “Super Intelligence.” The page itself continues to show a 403 Forbidden error instead of the study record.
    Difference
    1%
    Check dated 2026-10-26T16:39:06.000Z thumbnail image
  5. Check
    34 days ago
    Change Detected
    Summary
    The footer’s displayed site revision changed from v3.7.1 to v3.7.2.
    Difference
    0.2%
    Check dated 2026-10-19T21:52:32.000Z thumbnail image
  6. Check
    40 days ago
    Change Detected
    Summary
    The footer revision identifier changed from v3.7.0 to v3.7.1 on the 403 error page.
    Difference
    0.2%
    Check dated 2026-10-13T04:31:30.000Z thumbnail image
  7. Check
    48 days ago
    Change Detected
    Summary
    The study record area now displays a 403 Forbidden message with a Home link instead of study details.
    Difference
    0.5%
    Check dated 2026-10-05T21:35:14.000Z thumbnail image

Stay in the know with updates to IGF-1/IGFBP3 for ROP Prevention Clinical Trial

Enter your email address, and we'll notify you when there's something new on the IGF-1/IGFBP3 for ROP Prevention Clinical Trial page.